Answers are grounded in this paper and cite their sources.
This research work highlights AKR1B1 as a druggable target in metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC), which could provide the basis for the development of new chemotherapeutic agents. Moreover, our results indicate the potential of plasma AKR1B1 levels as a prognostic marker and diagnostic test for MASLD and associated HCC. Additionally, a major observation in this study was that AKR1B1 is associated with the promotion of the Warburg effect in HCC.
No takes yet. Share an insight, caveat, or question.
NP et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: